相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States
Anne M. Neilan et al.
CLINICAL INFECTIOUS DISEASES (2021)
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections
Anne M. Neilan et al.
AIDS AND BEHAVIOR (2021)
Use of HIV Pre-exposure Prophylaxis (PrEP) Associated With Lower HIV Anxiety Among Gay and Bisexual Men in Australia Who Are at High Risk of HIV Infection: Results From the Flux Study
Phillip Keen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Estimated Number of Men Who Have Sex With Men With Indications for HIV Pre-exposure Prophylaxis in a National Sexual Network Study
Kevin M. Weiss et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis
Rochelle P. Walensky et al.
ANNALS OF INTERNAL MEDICINE (2020)
National trends in HIV pre-exposure prophylaxis awareness, willingness and use among United States men who have sex with men recruited online, 2013 through 2017
Patrick S. Sullivan et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2020)
Regional Disparities in Qualified Health Plans' Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United States
Kathleen A. McManus et al.
JAMA NETWORK OPEN (2020)
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis RESPONSE
Rochelle P. Walensky et al.
ANNALS OF INTERNAL MEDICINE (2020)
National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 A Retrospective Cohort Study
Nathan W. Furukawa et al.
ANNALS OF INTERNAL MEDICINE (2020)
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H Mayer et al.
LANCET (2020)
Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men-20 Urban Areas, 2014 and 2017
Teresa Finlayson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
Rahul K. Nayak et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Estimating the Prevalence of HIV and Sexual Behaviors Among the US Transgender Population: A Systematic Review and Meta-Analysis, 2006-2017
Jeffrey S. Becasen et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2019)
Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis — United States, 2013–2018
Norma S. Harris et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015
Dawn K. Smith et al.
ANNALS OF EPIDEMIOLOGY (2018)
HIV Incidence, Prevalence, and Undiagnosed Infections in US Men Who Have Sex With Men
Sonia Singh et al.
ANNALS OF INTERNAL MEDICINE (2018)
Osteoporosis-Related Fractures in HIV-Infected Patients Receiving Long-Term Tenofovir Disoproxil Fumarate: An Observational Cohort Study
Ayami Komatsu et al.
DRUG SAFETY (2018)
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Ethan D. Borre et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study
Samuel M. Jenness et al.
CLINICAL INFECTIOUS DISEASES (2017)
Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand
Merlin L. Robb et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Costs of Expanded Rapid HIV Testing in Four Emergency Departments
Bruce R. Schackman et al.
PUBLIC HEALTH REPORTS (2016)
The promise and pitfalls of long-acting injectable agents for HIV prevention
Raphael J. Landovitz et al.
CURRENT OPINION IN HIV AND AIDS (2016)
The Clinical Role and Cost-Effectiveness of Long-Acting Antiretroviral Therapy
Eric L. Ross et al.
CLINICAL INFECTIOUS DISEASES (2015)
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
Jens D. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Surgery for Hip Fracture Yields Societal Benefits That Exceed the Direct Medical Costs
Qian Gu et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Cost of Implementing Rapid HIV Testing in Sexually Transmitted Disease Clinics in the United States
Ashley A. Eggman et al.
SEXUALLY TRANSMITTED DISEASES (2014)
Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm
Muazzam Nasrullah et al.
AIDS (2013)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study
Marie Helleberg et al.
AIDS (2012)
Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care
John A. Fleishman et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States
Paul E. Sax et al.
PLOS ONE (2012)
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
Pedro Cahn et al.
AIDS (2011)
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Eric S. Daar et al.
ANNALS OF INTERNAL MEDICINE (2011)
Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay
Pollyanna Chavez et al.
JOURNAL OF CLINICAL VIROLOGY (2011)
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
Robert M. Grant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
Y. Yazdanpanah et al.
CLINICAL INFECTIOUS DISEASES (2009)
Costs and quality of life associated with osteoporosis-related fractures in Sweden
F Borgström et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda
MJ Wawer et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
The cost of an emergency department visit and its relationship to emergency department volume
A Bamezai et al.
ANNALS OF EMERGENCY MEDICINE (2005)
分享论文
